The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity.

MLA

Agrawal NGB, et al. “The Effects of Modifying in Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity.” Journal of Clinical Pharmacology, vol. 44, no. 10, Oct. 2004, pp. 1125–31. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=106503005&authtype=sso&custid=ns315887.

APA

Agrawal NGB, Matthews CZ, Mazenko RS, Woolf EJ, Porras AG, Chen X, Miller JL, Michiels N, Wehling M, Schultz A, Gottlieb AB, Kraft WK, Greenberg HE, Waldman SA, Curtis SP, & Gottesdiener KM. (2004). The effects of modifying in vivo cytochrome P450 3A (CYP3A) activity on etoricoxib pharmacokinetics and of etoricoxib administration on CYP3A activity. Journal of Clinical Pharmacology, 44(10), 1125–1131.

Chicago

Agrawal NGB, Matthews CZ, Mazenko RS, Woolf EJ, Porras AG, Chen X, Miller JL, et al. 2004. “The Effects of Modifying in Vivo Cytochrome P450 3A (CYP3A) Activity on Etoricoxib Pharmacokinetics and of Etoricoxib Administration on CYP3A Activity.” Journal of Clinical Pharmacology 44 (10): 1125–31. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edb&AN=106503005&authtype=sso&custid=ns315887.